Abstract |
Systemic hypertension remains one of the leading cause of morbidity and mortality in the United States and throughout the world. Baxdrostat (CIN-107), a new drug developed by Roche is a selective aldosterone synthase inhibitor that is being evaluated as one of the potential treatments for hypertension, especially in patients with drug treatment-resistant hypertension. An increased level of aldosterone is associated with inflammation, systemic hypertension, and organ fibrosis, contributing to adverse cardiovascular events. A phase 2 trial, BrigHTN, showed promising results in demonstrating the efficacy of baxdrostat, where The HALO (efficacy and safety of baxdrostat in patients with uncontrolled hypertension) trial did not demonstrate any blood pressure-lowering benefit of baxdrostat when compared with the placebo. Several additional studies are now underway to evaluate the effectiveness of baxdrostat as an anti-hypertensive agent.
|
Authors | Subo Dey, William H Frishman, Wilbert S Aronow |
Journal | Cardiology in review
(Cardiol Rev)
(Aug 07 2023)
ISSN: 1538-4683 [Electronic] United States |
PMID | 37548462
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. |